PR
CRSP icon

PSP Research’s CRISPR Therapeutics CRSP Stock Holding History

PSP Research’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Sell
5,000
-4,500
-47% -$237K 0.15% 53
2026
Q1 		$452K Sell
9,500
-80
-0.8% -$4.22K 0.32% 35
2025
Q4 		$502K Buy
+9,580
New +$574K 0.44% 75

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PSP Research's CRSP Position: Q2 2026 in Review

PSP Research reduced its CRISPR Therapeutics (CRSP) stake by 47% in Q2 2026, selling an estimated $237K and leaving 5,000 shares worth $273K. The position accounts for 0.15% of the portfolio, ranked #53.

PSP Research first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $502K in Q4 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • PSP Research held 5,000 shares of CRISPR Therapeutics worth $273K as of Q2 2026.
  • PSP Research sold 4,500 CRISPR Therapeutics shares in Q2 2026, an estimated $237K.
  • CRISPR Therapeutics made up 0.15% of PSP Research's portfolio in Q2 2026, its #53 holding.
  • PSP Research first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's CRISPR Therapeutics position peaked at $502K in Q4 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.